Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 11.11% and 30.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.52% and 31.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Biohaven Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.
Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.